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Despite significant progress on the proportion of individuals who know their HIV status in
2020, Côte d’Ivoire (76%), Senegal (78%), and Mali (48%) remain far below, and key
populations (KP) including female sex workers (FSW), men who have sex with men
(MSM), and people who use drugs (PWUD) are the most vulnerable groups with a HIV
prevalence at 5–30%. HIV self-testing (HIVST), a process where a person collects his/her
own specimen, performs a test, and interprets the result, was introduced in 2019 as a
new testing modality through the ATLAS project coordinated by the international partner
organisation Solthis (IPO). We estimate the costs of implementing HIVST through 23
civil society organisations (CSO)-led models for KP in Côte d’Ivoire (N = 7), Senegal
(N = 11), and Mali (N = 5). We modelled costs for programme transition (2021) and
early scale-up (2022–2023). Between July 2019 and September 2020, a total of 51,028,
14,472, and 34,353 HIVST kits were distributed in Côte d’Ivoire, Senegal, and Mali,
respectively. Across countries, 64–80% of HIVST kits were distributed to FSW, 20–31%
to MSM, and 5–8% to PWUD. Average costs per HIVST kit distributed were $15 for
FSW (Côte d’Ivoire: $13, Senegal: $17, Mali: $16), $23 for MSM (Côte d’Ivoire: $15,
Senegal: $27, Mali: $28), and $80 for PWUD (Côte d’Ivoire: $16, Senegal: $144), driven
by personnel costs (47–78% of total costs), and HIVST kits costs (2–20%). Average
costs at scale-up were $11 for FSW (Côte d’Ivoire: $9, Senegal: $13, Mali: $10), $16
for MSM (Côte d’Ivoire: $9, Senegal: $23, Mali: $17), and $32 for PWUD (Côte d’Ivoire:
$14, Senegal: $50). Cost reductions were mainly explained by the spreading of IPO costs
over higher HIVST distribution volumes and progressive IPO withdrawal at scale-up. In
all countries, CSO-led HIVST kit provision to KP showed relatively high costs during the
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study period related to the progressive integration of the programme to CSO activities and
contextual challenges (COVID-19 pandemic, country safety concerns). In transition to
scale-up and integration of the HIVST programme into CSO activities, this model shows
large potential for substantial economies of scale. Further research will assess the overall
cost-effectiveness of this model.
Keywords: costs and cost analysis, scale-up, HIV self-testing, key populations, knowledge of HIV status,
diagnosis, screening, West Africa
INTRODUCTION
In Western and Central Africa, 5 million people are living with
HIV, representing a prevalence of 1.4% in 2019 (1). As in most
countries of the region, the epidemic is mixed in Côte d’Ivoire,
Senegal, and Mali, with national prevalence in 2018 ranging
between 0.4 and 2.6% and much higher prevalence at 5–30% in
hard-to-reach key populations (KP) including female sex workers
(FSW), men who have sex with men (MSM), and people who use
drugs (PWUD) (1). In 2019 in Western and Central Africa, HIV
prevalence was 10% for FSW, 14% for MSM, and 5% for PWUD
(1). Because of the HIV prevention gap among these groups, KP
contribute mostly to HIV transmission (2–4).
UNAIDS has set targets for 95% of people living with HIV to
know their status, 95% of known HIV-positive individuals to be
on antiretroviral therapy (ART), and 95% of those on ART to
have their viral load suppressed by 2030 (5). Despite significant
progress on the proportion of individuals who know their HIV
status (increase from 4% in 2000 to 67% in 2020), Western Africa
remains far below the first 90 UNAIDS target, with disparities
observed between Côte d’Ivoire (76%), Senegal (78%), and Mali
(48%) in 2020 (6).
Conventional facility-based HIV testing services (HTS) does
not adequately reach those KP due to stigma, discrimination,
and health services not responding to needs specific to each
group. Local civil society organisations (CSO) providing mostly
community-based HIV testing services using peer educators
have proven successful in reaching the core members of these
populations, linking, and retaining them into care (7, 8).
HIV self-testing (HIVST) is defined as a process where a
person collects his/her own specimen (oral fluid or blood),
performs an HIV test and interprets the result, often in private
(9). Following promising demonstration projects in Eastern
and Southern Africa (10–15), HIVST was introduced in 2019
as a new testing modality in West Africa with the ATLAS
project (Auto Test VIH, Libre d’Accéder à la connaissance de son
Statut) (16). The project is led by the French non-governmental
organisation Solthis—namely international partner organisation
(IPO) in this study—in consortium with the Institut de
Recherche pour le Développement, Ministries of Health, and
local implementing CSO in Côte d’Ivoire, Senegal, and Mali.
HIVST has the potential to overcome some of the existing
structural barriers to testing and to increase diagnosis coverage
among KP (primary distribution) and their peers, sexual partners
and clients (secondary distribution) not reached by conventional
HTS (17, 18).
OraQuick R© HIV self-tests have been subsidised by the Bill
andMelinda Gates Foundation, then proposed by Orasure Inc. at
US$2 per kit in 50 low- and middle-income countries for public
sector distribution (19). However, HIVST is still around twice
the price of standard HIV rapid diagnostic tests currently used
for HIV testing in Africa. In southern Africa, HIVST increased
diagnosis coverage and showed potential value for money for
key populations as a complement to current testing approaches
(9, 10, 20).
In this study, we estimate the costs of implementing HIVST
through CSO for KP in Côte d’Ivoire, Senegal, and Mali. We also
assess the costs of scaling up this model to guide project national
scale-up, propose costed operational plans, and inform on the
sustainability of this distribution model.
MATERIALS AND METHODS
Intervention Setting
HIVST kits were distributed through 23 CSO across Côte
d’Ivoire (N = 7), Senegal (N = 11), and Mali (N = 5)
from July 2019 to September 2020. Implementing partners’
key characteristics are presented in Table 1. The deployment
strategy identified three sequential intervention phases: (1)
development phase (June 2018–March 2019): all activities that
identify sustainable distribution models for each country, to
fully integrate HIVST into existing programmes; (2) start-
up phase [April 2019–July 2019 (Senegal/Mali), - October
2019 (Côte d’Ivoire)]: adaptation of self-testing information
materials to the local context, development of training manuals,
training of HIVST providers, sensitisation of key actors and
building partnerships with local partners (regardless of when
the costs were incurred), and other start-up costs; and 3) early
implementation phase (up to September 2020): demand creation,
HIVST kits distribution, and project supervision (Figure 1). In
each country, all CSO did not start HIVST kits distribution
at the same time, and this was accounted for in the cost
analysis by adjusting the length of the implementation period
by distribution channel. We costed community-based activities
used by CSO for reaching KP and excluded facility-based costs
corresponding toHIVST kits provision through index testing and
sexual health consultations, accounting for a small proportion
of CSO activities and outside the scope of this analysis. CSO1
(Senegal) is not technically a CSO but a public facility included
in the analysis because they provide community-based services
to PWUD.
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TABLE 1 | Overview of 1the ATLAS project’s implementing partners in Côte d’Ivoire, Senegal, and Mali.
Country Administrative Number of districts Civil society Distribution Number of trained HIVST kits
region covered organisation channel HIVST providers HIVST providers
Côte d’Ivoire Gbôklé, Nawa, San-Pédro 2 CSO1 FSW 13 9,605
MSM 4 4,172
Abidjan 1 2 CSO2 FSW 29 9,175
Abidjan 2 2 CSO3 FSW 20 15,944
MSM 6 6,812
PWUD 9 4,230
Mé, Abidjan 1 2 CSO4 MSM 7 2,177
Sud Comoé 1 CSO5 FSW 6 2,261
MSM 5 1,370
Mé, Sud Comoé 2 CSO6 FSW 13 5,181
MSM 8 2,511
Gbôklé, Nawa, San-Pédro 2 CSO7 FSW 8 7,044
MSM 3 4,406
Sub-total 131 74,888
Senegal Dakar, Thiès 11 CSO1 PWUD 22 1,862
Dakar, Thiès, Ziguinchor 18 CSO-Associations FSW 25 1,540
MSM 33 2,933
Dakar, Thiès 9 CSO-mobile clinics FSW 4 810












11 CSO2 FSW 78 22,400
MSM 20 3,360
Bamako, Segou, Sikasso 5 CSO3 FSW 31 20,910
Kayes, Koulikoro 12 CSO4 MSM 19 12,321




HIVST, HIV Self-Testing kit; FSW, Female Sex workers; MSM, Men who have Sex with Men; PWUD, People who use drugs.
Cost Data Collection and Analysis
The costing teams followed the Global Health Cost Consortium
guidelines and collaboratively analysed data, ensuring
consistency of methods across countries (21–23). We used
the provider’s perspective. We conducted an incremental cost
analysis, where only additional resources needed to introduce
HIVST to existing service provision were considered. These
incremental costs were collated from the IPO and implementing
partners’ financial expenditures and each line item was
categorised by input type and distribution model (top-down
costing approach) (24). Inputs were categorised into start-up,
capital, and recurrent costs. Inputs were allocated to distribution
sites following predefined allocation factors, based on project
monitoring and evaluation data, including the percentage
of HIVST distributors in each site, estimated cohort size of
HIV-positive patients followed by the CSO, percentage of kits
distributed, and percentage of direct expenditures, which is a
weighted average of the preceding allocation factors. Further
details on the methods and allocation factors can be found
in Appendix Table 1, and elsewhere (25–27). To estimate
economic costs, the expenditure analysis was complemented
by a valuation, with market prices or financial data provided
by the implementers, of all other resources used in the delivery
model (donated services such as personnel time at the CSO
headquarters and in the field, not paid by the ATLAS project).
Finally, a time-motion study was conducted to observe staff
providing HIVST alongside other services and allocate personnel
costs based on the time spent on each activity (28, 29). The
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FIGURE 1 | Description of the ATLAS project’s three HIV self-testing (HIVST) deployment phases in Côte d’Ivoire, Senegal, and Mali over 2018–2020.
HIVST kit cost was US$2.68 for Côte d’Ivoire and US$3.08 for
Senegal and Mali. Start-up, training, and all other capital costs
were annualised using a discount rate of 3%. All costs were
estimated in 2020 USD dollars using annual exchange rates.
Total costs and average cost per kit distributed were estimated at
the country level, at the CSO level and per channel.
Sensitivity Analysis of Costs
We conducted a series of one-way sensitivity analyses, using
tornado diagrams, to assess the impact of key cost assumptions
on the average cost per HIVST kit distributed. We varied the
discount rate used to annualised costs to 0 and 16% (base case
is 3%) to capture the impact of not discounting or using a
higher local central bank discount rate such as in Mali (30). We
evaluated the impact of applying alternative allocation factors
that is swapping percentage trained distributors to percentage
cohort size for IPO expenditures. We varied annualisation
(economic life years) time frames: training & sensitisation were
varied between 1 and 3 years (base: 2 years), project development
life between 5 and 15 years (base: 10 years), and start-up life
(training, sensitisation and other costs incurred during this
phase) between 2.5 and 7.5 years (base: 5 years) to assess the
impact of the assumed project life years on costs. For Senegal only
due to data availability, we swapped the allocation of field-based
personnel costs from using percentage HIVST time observed
during the time-motion study to using percentage HIVST time
reported by study participants. Finally, episodes of violence
against MSM occurred during the study period, and CSO had
to suspend their activities in Senegal and Mali. The COVID-
19 pandemic also led to reduced/suspended activities (Figure 1),
therefore we also estimated the average cost per target HIVST
distribution volumes.
Scale-Up Cost Model and Scenario
Analysis
We also modelled costs at scale-up when HIVST kit distribution
volumes would increase following each country’s National
Strategic Plan for HIV testing to predict the variation of average
cost between the implementation and scale-up phases. The
production function, developed by Cobb and Douglas, describes
the relationship between outputs and factors of productions
(inputs) (31). Accounting cost functions follow step-by-step the
intervention production process as close as possible to reality
(22, 32). They identify fixed and variable costs, typically assumed
to vary linearly with the scale such as that used in input-output
analysis as originally developed by Leontief (33, 34). It should
be noted that with the exception of training costs (variable cost)
and sensitisation costs (fixed cost) considered in the scale-up
model, all other costs incurred during the development and start-
up phases are considered one-off costs incurred at the start of
the programme and therefore, are excluded from the costs of
scaling-up. The model algebra is presented here, the detailed






with VCj = UCj · Sj
Where:
C: Total cost
j: inputs differentiating intervention levels—international,
national, district, and community
FCj: Fixed cost (independent of Sj) for fixed input j (e.g.,
building, personnel at central level)
Frontiers in Public Health | www.frontiersin.org 4 May 2021 | Volume 9 | Article 653612
d’Elbée et al. HIV Self-Testing Costs in West Africa
TABLE 2 | Model structure—Accounting cost function.
Intervention level Type of costs Cost inputs Scale variable*
International Fixed costs S2. Sensitisation—Coordination
R1. Personnel and Per diems—Headquarters
IPO coordination
Variable costs None
National Fixed costs C1. Buildings and storage
C2. Equipment
C3. Vehicles
C4. Other capital costs
S2. Sensitisation—IPO country
R2. Personnel and Per diems—Headquarters
IPO country
Variable costs S1. Trainings (start-up phase only) Number of new providers to train
R6. Vehicle operation and
maintenance/transportation
Total number of HIVST providers
R7. Building operation and maintenance Total number of HIVST providers
R8. Other recurrent costs Total number of HIVST providers
Sub-national—Implementing partners Fixed costs None
Variable costs R3. Personnel and Per diems—Headquarters
Implementing partner
Total number of HIVST providers
Local—HIVST distribution areas Fixed costs None
Variable costs R4. Personnel and Per diems—Field (HIVST
distributors)
Total number of HIVST providers
R5. HIV self-testing kits (implementation phase only) Number of HIVST kits to distribute
*The selection of scale variables was done in a way to account for the fact that the project is in early implementation phase (HIVST kits distribution targets not always reached by CSO
in early phase) and the COVID-19 pandemic impact (reduced field activities), meaning CSO were not working at full capacity during the observed costing period. Therefore, the model
uses predominantly the number of providers as scale up variable rather than the number of HIVST kits distributed during our observed period to limit the risks of bias. The number of
kits to distribute is used to estimate projected costs based on HIVST volume distribution targets for each year 2021–2023.
IPO, International Partner Organisation.
VCj: Variable cost for input j (e.g., field personnel, HIVST kits)
UCj:Unit cost per variable inputs j for one output (the type of
unit depends of each category): new staff to train, HIVST kits to
distribute, etc.
Sj: Scale variable for input j to reach desired number
of outputs: number of new providers required for scale-up,
total number of providers at scale-up, number of HIVST kits
to distribute.
In anticipation of planned project scale-up by respective
country ministries of health and post-ATLAS transition, we
conducted a series of scenario analyses varying some of the key
model parameters by country and by scale-up year, considering
2021 as a transition year, 2022 partial scale-up, and 2023 as
full scale-up. Four potential scenarios are presented in Table 3.
Logistical and contextual challenges with CSO-led delivery
channels to criminalised KP, and current donors’ commitments
for funding, were noted to cause challenges leading to uncertainty
related to the timely attainment of targets. We therefore
anticipate that those programmatic objectives might not be
reached. Accounting for this would provide more nuanced scale
economies, and we applied different percentages for reaching
targets—higher percentages in Mali, where more funding is
already secured (scenario 1). IPO’s goal to progressively disengage
to promote local project ownership overtime was considered.
Note that we still account for 15% of international costs in
2023 because we assume another coordination component will
still exist (and incur costs) within the local health system at
central level. Year 2023 would then represent what it costs for
the country to support HIVST post-ATLAS (scenario 2). We
also assessed the impact of optimising delivery channels by
simplifying the model of partners/sub-partners and decreased
CSO headquarter costs by 20%, which is reasonable to assume
when evaluating interventions transitioning from pilot (ATLAS)
to routine implementation phase (scenario 3) (35). Finally, we
conducted country-specific simulations to account for varying
HIVST kit cost for each year considering factors such as bulk
buying, maritime provision instead of airways (except Mali),
and integrating HIVST delivery chain with other health supplies
(scenario 4). Finally, we combined all scenarios above to assess
the global impact on average costs at scale per KP and scale-
up year.
This study was approved by the London School of Hygiene
and Tropical Medicine (n◦ 17141/RR/13198, 31st March 2019)
WHO Ethic Research Committee (n◦ERC0003181, 7th August
2019), and by three national ethic committees: Comité National
d’Ethique des Sciences de la vie et de la Santé de Côte
d’Ivoire (n◦049-19/MSHP/CNESVS-kp, 28th May 2019), Comité
National d’Ethique pour la Recherche en santé du Sénégal
(n◦SEN19/32, 26th July 2019), and Comité d’Ethique de la
Faculté de Médecine de Pharmacie et d’Odonto-Stomatologie de
l’Université des Sciences et des Techniques de Bamako au Mali
(n◦2019/88/CE/FMPOS, 14th August 2019).
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TABLE 3 | Selected parameters for the scenario analysis of costs at scale-up in Côte d’Ivoire, Senegal, and Mali (baseline: all parameters at 100%).
Scenario 1 Scenario 2 Scenario 3 Scenario 4
Reaching HIVST distribution
volume targets
(% of target achieved)
Progressive disengagement
of IPO
(% reduction of IPO costs)
Implementing partners
headquarter costs
(% reduction of IP costs)
HIVST kit cost based on
volumes
(% reduction of original kit cost)
2021 2022 2023 2021 2022 2023 2021 2022 2023 2021 2022 2023
Côte d’Ivoire −25% −25% −30% As in baseline −50% −85% −20% −20% −20% −9% −9% −9%
Senegal −25% −25% −30% As in baseline −50% −85% −20% −20% −20% −17% −17% −17%
Mali −20% −20% −25% As in baseline −50% −85% −20% −20% −20% −13% −13% −13%
IPO, International Partner Organisation; IP, Implementing Partner.
RESULTS
Programme Outcomes in Côte d’Ivoire,
Senegal, and Mali
During the costing period, 51,028, 14,472, and 34,353 HIVST
kits were distributed in Côte d’Ivoire, Senegal, and Mali through
a total of 161, 48, and 191 peer educators, respectively. These
volumes corresponded to 68% (Côte d’Ivoire), 103% (Senegal),
and 42% (Mali) of planned targets. The average number of
HIVST kits distributed was 7,290 (range: 1,295–16,513) across 7
CSO in Côte d’Ivoire, 3,618 (range: 422–7,193) across the main
four models composed of 11 CSO in Senegal (CSO-Associations,
CSO-Mobile clinics, CSO-independent distributors, and the
public partner working with PWUD only), and 6,871 (range:
2,688–17,891) across 5 CSO in Mali. In Côte d’Ivoire, 66% of
kits (N = 33,647) were distributed to FSW, 26% (N = 13,250)
to MSM, and 8% (N = 4,131) to PWUD. In Senegal, 64% of kits
(N = 9,338) were distributed to FSW, 31% (N = 4,472) to MSM,
and 5% (N = 662) to PWUD. In Mali, 80% of kits (N = 27,528)
were distributed to FSW, and 20% (N= 6,825) to MSM.
Project Total Costs and Average Costs per
Kit Distributed, Distribution Target
In Côte d’Ivoire, the total distribution costs were calculated as
$440,648, $201,910, and $65,691 for FSW, MSM, and PWUD,
respectively (Table 4). Start-up phase accounted for 25, 23, and
26% of total costs for FSW,MSM, and PWUD, respectively, while
the development phase only accounted for 2% across key groups.
Personnel costs at various intervention levels accounted for a
substantial portion of total costs, at 47% for FSW, and 50% for
MSM and PWUD, followed by HIVST kits costs at 20, 18, and
17% (Figure 2). Average cost per HIVST kit distributed were $13,
$15, and $16 for FSW, MSM, and PWUD.
For Senegal, total intervention costs were $159,393, $120,374,
and $95,091 for FSW, MSM, and PWUD (Table 4). Start-up
phase costs were 17% for FSW and MSM, and 5% for PWUD,
and at a mean of 5% for development phase costs across groups.
Personnel costs were 51%, 57%, and 78% of total costs while
HIVST kits costs were 18%, 11%, and 2% for FSW, MSM, and
PWUD, respectively (Figure 2). Average costs per kit were $17,
$27, and $144 for FSW, MSM, and PWUD.
Finally, in Mali, total costs were $438,553 and $188,159 for
FSW, andMSM (Table 4). Start-up phase and development phase
costs accounted on average for 13% and 3% of total costs across
groups. Personnel costs were 53%, and 61% of total costs, while
HIVST kits costs were at 19% and 11% for FSW and MSM,
respectively (Figure 2). Average cost per kit were $16 and $28 for
FSW and MSM.
While the share of start-up costs as percentage of total costs
was comparable between target groups in Côte d’Ivoire and in
Mali, it differed in Senegal because the CSO delivering to PWUD
were small organisations, hence being allocated a low share of
start-up costs. Because the start-up period was longer in Côte
d’Ivoire (6 months) compared to the one in Senegal and Mali (3
months), start-up costs as percentage of total costs were higher in
Côte d’Ivoire.
Wide variations of average costs per HIVST kit distributed
were found between CSO (Appendix Tables 2a–c). In Côte
d’Ivoire, average cost per kit distributed ranged $9–$27 for FSW,
$10–$29 for MSM, and only one CSO worked with PWUD.
In Senegal, average costs were $13–$32 for FSW, $25–$28
for MSM, and $121–$156 for PWUD. In Mali, average cost
per kit distributed ranged $15–$27 for FSW, and $17–$59 for
MSM. In Senegal, CSO-Associations had lower average costs
than CSO-Independent distributors (mean: $19 vs. $23), but
overall distributed less HIVST kits (5,834 vs. 6,953 kits) to FSW
and MSM.
The major driver of these cost differences both between and
within key groups for all countries was the number of kits
distributed per dispensing agent, except in Côte d’Ivoire where
the average number of kits distributed per dispensing agent
was comparable between groups. Another important driver of
cost variation between and within groups for all countries was
the total number of HIVST kits distributed by a CSO. An
increase of any of these two drivers would lead to a reduction
in average costs.
Sensitivity Analysis of Costs Results
Appendix Figure 1 presents results from the univariate
sensitivity analyses by key groups for Côte d’Ivoire (1a), Senegal
(1b), and Mali (1c). Our unit costs per HIVST kit distributed
remained robust when key cost parameters were varied. In
Côte d’Ivoire, varying life of start-up sensitisation and training
between 1 and 3 years had the strongest effect on costs ranging
between $12–$17, $14–$19, and $14–$20 for FSW, MSM and
PWUD, respectively. The life year of development and start-up
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TABLE 4 | Observed total and average intervention costs by intervention phase and key group—Côte d’Ivoire, Senegal, and Mali.
Côte d’Ivoire—Global estimates
FSW MSM PWUD
$ % $ % $ %
Intervention phases
Development 7,612 2% 3,518 2% 1,118 2%
Start–up (start–up and other costs) 120,874 27% 52,238 26% 18,687 28%
Implementation 312,162 71% 146,153 72% 45,887 70%
Total annual costs 440,648 201,910 65,691
HIVST kits distributed 33,647 13,250 4,131
Average cost per HIVST kit distributed 13 15 16
Senegal—Global estimates
FSW MSM PWUD
$ % $ % $ %
Intervention phases
Development 8,262 5% 5,684 5% 4,754 5%
Start-up (start-up and other costs) 35,628 22% 25,579 21% 9,648 10%
Implementation 115,502 72% 89,111 74% 80,689 85%
Total annual costs 159,393 120,374 95,091
HIVST kits distributed 9,338 4,472 662
Average cost per HIVST kit distributed 17 27 144
Mali—Global estimates
FSW MSM
$ % $ %
Intervention phases
Development 11,544 3% 5,434 3%
Start-up (start-up and other costs) 74,345 17% 29,633 16%
Implementation 352,664 80% 153,093 81%
Total annual costs 438,553 188,159
HIVST kits distributed 27,528 6,825
Average cost per HIVST kit distributed 16 28
HIVST, HIV Self-Testing kit; FSW, Female Sex workers; MSM, Men who have Sex with Men; PWUD, People who use drugs.
phases, allocation factor swapping (for FSW and MSM) had a
moderate effect with less than a dollar variation. The variation
of discount rate almost had no effect on costs. In Senegal, the
discount rate applied had the strongest effect with average
costs varying between $17–$19, $26–$30, and $141–$163 for
FSW, MSM, and PWUD, respectively due to higher proportion
of capital costs compared to Côte d’Ivoire. Allocation factor
swapping from trained distributors had an effect on average
costs for PWUD (reduction to $127), while swapping from
time-motion study results had no effect. In Mali, swapping of
allocation factors has the strongest effect, but overall, average
costs only varied by <2 dollars suggesting our average costs were
quite robust.
Reaching HIVST distribution targets greatly reduced costs
(not presented in Appendix Figure 1). Average cost per HIVST
kit distributed were $9, $9, and $16 for FSW, MSM, and PWUD,
assuming distribution targets were reached in Côte d’Ivoire.
In Senegal, average costs per kit were $24, $23, and $47 for
FSW, MSM, and PWUD assuming distribution targets were
reached. Finally, in Mali, average cost per kit would be much
lower if targets were reached, at $7 and $8 for FSW and
MSM, respectively.
Cost at Scale-Up Following National
Strategic Plans
Costs at scale-up for each year of the National Strategic Plans
are presented by country, year, and key groups in Figure 3, with
details in Appendix Tables 3a–c.
Over the period 2021–2023, costs per kit distributed are
on average at $9 (FSW and MSM), and $14 (PWUD) in
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FIGURE 2 | Average intervention costs by inputs for each key group—Côte d’Ivoire, Senegal, and Mali. *For PWUD in Senegal, costs are presented on this figure
divided by 10 for scale purpose.
FIGURE 3 | Total and average intervention costs in transition (2021) and at scale-up (2022–2023) by country and key population.
Côte d’Ivoire; $13 (FSW), $23 (MSM) and $50 (PWUD) in
Senegal; and $10 (FSW), and $17 (MSM) in Mali. We note the
significant reduction of average costs at scale-up vs. observed
average costs for FSW and MSM in Côte d’Ivoire, PWUD in
Senegal, and all groups in Mali. Across countries, years, and
key groups, the trend is an overall increase in total costs as
expected. Although we estimate variation between countries
and key groups, in transition and scale-up, overall cost drivers
are fixed costs such as sensitisation activities, and headquarter-
based personnel costs at national and sub-national level, and
variable costs such as training and HIVST kits costs (varying
with HIVST distribution targets). In Senegal, we estimate
higher personnel costs at CSO level (headquarter- and field-
based).
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Scenario Analysis of Scale-Up Costs
As the scale-up model does not account for other contextual
factors related to the transition post-ATLAS, analyses of plausible
scale-up scenario are presented in Appendix Figures 2a–c.
For all countries and key groups, we find that HIVST volumes
are the major determinants of costs per HIVST kit distributed
(economies of scale), followed by IPO withdrawal starting in
2022, reduction of implementers’ central costs, and the estimated
reduction of HIVST kit price. Accounting for all these factors
together would increase estimated scale-up average costs between
$9 (FSW−2023) and $18 (PWUD−2021) in Côte d’Ivoire, from
$12 (FSW−2023) to $65 (PWUD−2021) in Senegal, and from $9
(FSW−2023) to $21 (MSM−2021) in Mali.
DISCUSSION
In this study, we estimated the cost of implementing HIVST for
KP and their partners in three West African countries. Across
countries, we found that costs ranged between $13-$17 for FSW,
$15-$28 for MSM and $16-$144 for PWUD. Note that PWUD
channels distribute small quantities of HIVST kits, and average
costs are therefore highly sensitive to scale of operation between
CSO. Major cost contributors were personnel costs at central
and regional intervention levels. Start-up costs across countries,
corresponding to sensitisation of CSO and other partners, and
training costs contributed to 10–28% of total costs. This is due
to the complexity and lengthy process of building partnerships
with numerous local CSO and involving key stakeholders in an
intervention fully integrated with existing health care delivery
services for KP. Costs per kit distributed were lowest in Côte
d’Ivoire and highest in Senegal. Across countries, average costs
per HIVST were lowest for FSW, followed byMSM, then PWUD.
These differences could be explained by HIVST volumes by
channels with a total of 70,513 kits distributed to FSW, 24,547
kits to MSM, and 4,793 kits to PWUD during our costing
period. However, it is likely that other factors played a role.
For instance, in Senegal and Mali, several episodes of violence
against MSM were reported at different time points (unrelated
to the programme), and CSO had to suspend their field activities
for security reasons, contributing to an unstable, and therefore
costly, delivery system of kits for this group. In Mali, there
were safety concerns due to the country’s Coup d’Etat in August
2020, and ongoing armed conflict with intermittent suspension
of fieldwork activities. Indeed, estimated average costs per kit
would be as low as $7 (FSW) and $8 (MSM) assuming targets
were reached in Mali. Finally, the COVID-19 pandemic also
led to reduced (Côte d’Ivoire and Mali) or suspended (Senegal)
activities during 2–3 months, leading to high observed costs,
although self-testing was shown to be a timely alternative to
provider-delivered HIV testing during periods of lockdown and
reduced social interactions (36).
Important average costs variations between CSO were
observed. High number of kits distributed per dispensing agent
led to a reduction in average costs and depended on the type
of HIVST distribution activity with high distribution in bars
and brothels, and low distribution in small gatherings at KP’s
house. CSO-specific policy with monthly maximum targets of
kits distribution per agent could potentially lead to higher average
costs. Small number of HIVST kits distributed per CSO was
also driving average costs high and was explained by the type of
population reached (e.g., CSO working with PWUD only deliver
small HIVST volumes), and the CSO size. To a lesser extent
in Mali, numerous HIVST delivery models per CSO (some not
presented here such as Index and STI services) could lead to
higher spreading of central costs across models, and therefore,
a reduction of average costs.
Our costs were comparable to other community-based HIVST
costing studies, many of them arising from the STAR (HIV Self-
Testing AfRica) project (37, 38)1. Across six southern Africa
countries (Malawi, Zambia, Zimbabwe, South Africa, Lesotho,
eSwatini), costs per kit distributed ranged from $8 for door-to-
door distribution in Malawi to $18 for mobile integration (more
similar to the ATLAS programme) in South Africa (25, 26, 39, 40).
Although HIVST volumes were generally higher as targeting the
general population and benefiting from economies of scale, many
of these models were highly vertical incurring significant above
service level costs. However, cost per kit distributed to South
African FSW and MSM were lower than our observed costs at $4
and $6, respectively, for 19,901 and 12,218 kits distributed. This
is partly explained by the high number of HIVST delivery models
in South Africa and sharing of central costs across models (39).
Additionally, our costs were comparable to one study in Côte
d’Ivoire reporting HTS unit costs from the Ivorian Programme
National de Lutte contre le Sida (PNLS) for FSW and MSM at
$16 and $21, respectively (41). However, one should consider the
reduced costs to the kit user (in terms of transportation cost or
opportunity cost for example), and therefore to society, when
comparing community-based HIVST distribution and facility-
based provider-delivered HTS costs (42, 43).
The scale-up model suggests that these early-stage CSO-led
community-based HIVST distribution programmes can exhibit
economies of scale. When comparing year 2023 with observed
costs, we estimated variable scale economies between groups
and countries, with about 56% (FSW), 63% (MSM), and 10%
(PWUD) of average cost reduction in Côte d’Ivoire, 19% (FSW),
12% (MSM), and 66% (PWUD) in Senegal, and 35% (FSW), 41%
(MSM) inMali. Beyond scale economies, other contextual factors
were considered, such as accounting for progressive integration
of the ATLAS project to existing CSO and withdrawal of the
IPO. The scenario analysis suggests that, overall, even if target
were not reached, costs at scale would decrease in Côte d’Ivoire
(except PWUD) andMali. However, results are more nuanced for
Senegal with constant (FSW) or increasing average costs (MSM,
PWUD) due to high fixed costs at sub-national level.
Our study has several limitations. First, our outcome metric
“per HIVST kit distributed” does not fully capture the HIVST
cascade. For example, there remain uncertainties related to the
true percentage of kits use, the actual final users of the kit (e.g.,
HIVST distribution through a FSW model could also be used
1Ahmed N, Terris-Prestholt F, Ong JJ, d’Elbée M, Rotolo S, Johnson C, et al. A
systematic literature review of costs and cost-effectiveness analyses of HIV testing
services in sub-Saharan Africa.
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by their clients), and among those with a reactive HIVST the
linkage rate to confirmatory testing. However, there is now large
evidence on high acceptability of HIVST kits in the general
population and among KP (11, 13, 14, 17, 18, 44–47). Moreover,
the ATLAS programme is currently trying to evaluate the impact
of HIVST on HIV case finding and ART initiation, these data will
then feed in a modelling analysis to estimate cost-effectiveness.
Second, total and average costs are estimated across a diverse
range of CSO for each country leading to inevitable cost variation
by distribution channel. Third, the COVID-19 pandemic led to
reduced/suspended activities during a trimester for some CSO,
but also encouraged the use of HIVST by other actors as a
timely alternative to HTS in response to lockdown and social
distancing, therefore, its impact on costs and project outcomes
is difficult to assess (36). Fourth, scale-up costs and scenario
analysis were conducted in collaboration with the implementer to
ensure model assumptions were close to reality, but these remain
arbitrary and should be interpreted with caution.
In three countries of West Africa, HIVST kit provision to
KP through CSO had higher initial costs during the study
period, related to the progressive integration of HIVST to
CSO activities, and a challenging implementing environment
(criminalised KP, pandemic COVID-19, security concerns). The
analysis of costs at scale suggests that, in transition to scale-up
and further integration of the ATLAS project, this model shows
large potential for substantial economies of scale as programmes
scale-up and mature.
Recent modelling studies in Cameroon, Senegal, Côte d’Ivoire,
and South Africa show that key populations and their sexual
partners, particularly FSW and their clients, can play an
important role in HIV transmission in both low and high HIV
prevalence settings due to prevention gaps (3, 4, 48). HIV
prevention and treatment strategies targeting these groups are
essential for controlling the HIV epidemic and are likely to
provide good value for money. The CSO-led HIVST delivery
model is particularly relevant as it remains today the most
promising strategy for reaching KP, their sexual partners and
clients of FSW not accessing HIV testing, so-called “hidden
populations.” Further research will assess the overall cost-
effectiveness of the CSO-led HIVST delivery programme.
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